n-3 polyunsaturated fatty acid requirements of term infants

被引:0
|
作者
Gibson, RA
Makrides, M
机构
[1] Univ Adelaide, Womens & Childrens Hosp, Dept Obstet & Gynaecol, N Adelaide, SA 5005, Australia
[2] Child Hlth Res Inst, Child Nutr Res Ctr, N Adelaide, SA 5042, Australia
来源
关键词
n-3 polyunsaturated fatty acids; long-chain polyunsaturated fatty acids; infant formula; neural development; neurologic development; term infants; docosahexaenoic acid; DHA; breast milk; human milk;
D O I
暂无
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
The benchmarks for human nutrient requirements are the recommended dietary intakes (RDIs). However, the RDIs are set to prevent a clinical deficiency state in an otherwise healthy population and there are few nutrient recommendations set with the goal of achieving an optimal or maximal state of nutrition and health. This is becoming an increasing challenge with the introduction of many nutraceuticals and functional foods, a prime example being the debate surrounding the introduction of long-chain polyunsaturated fatty acids (LCPUFAs) into infant formulas. Most expert nutrition committees have used the fatty acid composition of breast milk as a basis for recommendations for infant formulas, with little information on the minimum absolute requirement for essential PUFAs. It has been difficult to determine a minimum requirement for fatty acids because I) LCPUFAs can be synthesized from precursor fatty acids, 2) plasma n-3 LCPUFA concentrations representing deficiency and sufficiency are not clearly defined, and 3) there are no recognized clinical tests for n-3 LCPUFA deficiency and sufficiency. Therefore, there is a clear need to associate a measure of LCPUFA status with a specific functional outcome before any recommendations can be made for achieving optimal or maximal LCPUFA status.
引用
收藏
页码:251S / 255S
页数:5
相关论文
共 50 条
  • [31] The Myristic Acid:Docosahexaenoic Acid Ratio Versus the n-6 Polyunsaturated Fatty Acid:n-3 Polyunsaturated Fatty Acid Ratio as Nonalcoholic Fatty Liver Disease Biomarkers
    Antunes, Marina Masetto
    Godoy, Guilherme
    Curi, Rui
    Visentainer, Jesui Vergilio
    Bazotte, Roberto Barbosa
    METABOLIC SYNDROME AND RELATED DISORDERS, 2022, 20 (02) : 69 - 78
  • [32] n-3 polyunsaturated fatty acids and immune function
    Wu, DY
    Meydani, SN
    PROCEEDINGS OF THE NUTRITION SOCIETY, 1998, 57 (04) : 503 - 509
  • [33] N-3 polyunsaturated fatty acids and cardiac mortality
    Singleton, CB
    Walker, BD
    Campbell, TJ
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 2000, 30 (02): : 246 - 251
  • [34] n-3 polyunsaturated fatty acids and cardiovascular diseases
    Nordoy, A
    Marchioli, R
    Arnesen, H
    Videbæk, J
    LIPIDS, 2001, 36 : S127 - S129
  • [35] n-3 polyunsaturated fatty acids and breast cancer
    Lhuillery, C
    Cognault, S
    Germain, E
    Chajes, V
    Bougnoux, P
    BREAST CANCER - ADVANCES IN BIOLOGY AND THERAPEUTICS, 1996, : 59 - 65
  • [36] N-3 Polyunsaturated Fatty Acids and Gut Microbiota
    Jayapala, Hettiarachchige Priyanga Sajeewanie
    Lim, Sun Young
    COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, 2023, 26 (05) : 892 - 905
  • [37] N-3 polyunsaturated fatty acids and brain aging
    Nyakas, C.
    Hogyes, E.
    Kacsandi, A.
    Felszeghy, K.
    Mehra, R. D.
    Luiten, P. G. M.
    ACTA PHYSIOLOGICA HUNGARICA, 2010, 97 (04) : 465 - 466
  • [38] Human requirement for n-3 polyunsaturated fatty acids
    Simopoulos, AP
    POULTRY SCIENCE, 2000, 79 (07) : 961 - 970
  • [39] n-3 polyunsaturated fatty acids and coronary thrombosis
    Kristensen, SD
    Iversen, AMB
    Schmidt, EB
    LIPIDS, 2001, 36 : S79 - S82
  • [40] N-3 polyunsaturated fatty acids and allergic disease
    Prescott, SL
    Calder, PC
    CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE, 2004, 7 (02): : 123 - 129